Format

Send to

Choose Destination
Expert Opin Pharmacother. 2015 Mar;16(4):547-57. doi: 10.1517/14656566.2015.997211. Epub 2014 Dec 25.

Management of constipation in Parkinson's disease.

Author information

1
Raul Carrea Institute for Neurological Research (FLENI), Neuroscience Department, Movement Disorders Section , Buenos Aires , Argentina.

Abstract

INTRODUCTION:

Constipation is a frequent non-motor feature of Parkinson's disease (PD). It is the most common gastrointestinal symptom of the disease and it can precede motor symptoms by as much as 20 years. Constipation can produce discomfort and affect activities of daily living, productivity and quality of life, thus warranting early diagnosis and treatment.

AREAS COVERED:

In this review, the safety and efficacy of traditional and novel strategies for constipation management will be discussed. A treatment algorithm for constipation in PD will be presented.

EXPERT OPINION:

Polyethylene glycol and lubiprostone are first-line compounds recommended by evidence-based medicine guidelines for the treatment of constipation due to slow colonic transit in PD. Management of constipation secondary to defecatory dysfunction due to pelvic floor dyssynergia can be done by levodopa or apomorphine injections, botulinum toxin type A injection into the puborectalis muscle, and nonpharmacological interventions, like biofeedback therapy or functional magnetic stimulation, which showed some benefit in PD patients with constipation, but in general more extensive studies are warranted.

KEYWORDS:

Parkinson’s disease; algorithm; constipation; gastrointestinal; lubiprostone; polyethylene glycol

PMID:
25539892
DOI:
10.1517/14656566.2015.997211
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center